June 11, 2024

GrowGeneration (GRWG) Germinates New B2B Portal for Hydroponic Retailers and Garden Centers, Nationwide

Hydroponic and organic garden retailer, GrowGeneration Corp. (GRWG) has announced the launch of the HRG Marketplace, a new B2B portal developed by the Horticultural Rep Group (HRG), its wholesale division and a leading distributor in the hydroponic industry. This innovative portal is set to transform how hydroponic retailers and garden centers across the United States… [Read More]
June 11, 2024

MicroCap Moves: Creative Realities (CREX) Joins Russell Microcap and Appoints VP of New Business Development

PRISM AdTech and Media Index company and leader in digital signage solutions, Creative Realities (CREX) has announced the appointment of David Schultz, as Vice President of New Business Development. Schultz had previously worked for notable companies including Appspace, Cisco Systems, NEC Corporation, Hitachi America, Toshiba Display Solutions and, most recently, with Stratacache. Additionally, the company… [Read More]
June 11, 2024

BrainsWay Advances Deep Transcranial Magnetic Stimulation for Major Depressive Disorder

Global medical technology company, BrainsWay Ltd. (Nasdaq: BWAY), has initiated a prospective, randomized, controlled, multicenter clinical trial evaluating an accelerated treatment protocol for the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system to treat major depressive disorder (MDD). The company’s share price settled up +3.42% on Monday following the news. BrainsWay is currently recruiting… [Read More]
June 11, 2024

Stocks making the biggest moves premarket: Eli Lilly, General Motors, Shopify

Find out which businesses are moving the markets in pre-market trading. Eli Lilly — Eli Lilly’s stock gained 2% following a recommendation from a committee of FDA consultants for the authorization of its Alzheimer’s medication, donanemab. General Motors — The vehicle manufacturer’s stocks increased by over 1% as its board approved a $6 billion share… [Read More]
June 10, 2024

Replimune Rises on Positive Melanoma Study Data

Shares in biotechnology company Replimune Group (Nasdaq: REPL), climbed nearly 15% on Monday morning after the company reported positive topline results from the primary analysis of its IGNYTE clinical trial evaluating RP1 plus nivolumab in anti-PD1 failed melanoma. The results showed that one-third of patients receiving RP1 plus nivolumab responded to treatment, with all responses… [Read More]
June 07, 2024

Vaccinex Completes Last Patient Visit in Alzheimer’s Disease Study

Biotechnology company, Vaccinex, Inc. (Nasdaq: VCNX), has completed the last patient visit in its randomized, placebo-controlled double-blind study of pepinemab treatment for Alzheimer’s disease. Vaccinex said it expects to lock the trial database in June and is on track to report key outcomes in July. Pepinemab has been well-tolerated in clinical trials that enrolled a… [Read More]
June 07, 2024

Vanda Pharmaceuticals Soars on Unsolicited Takeover Bid

Shares in Vanda Pharmaceuticals (Nasdaq: VNDA) soared on Thursday after the company confirmed that it had received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the company for $8.00 per share in cash. Vanda stated that its Board of Directors is consulting with independent financial and legal advisors and will… [Read More]
June 07, 2024

Stocks making the biggest moves premarket: GameStop, Lyft, Vail Resorts and more

Explore the front-runners in today’s pre-opening stock market moves. GameStop — This viral stock fell 5% before the market opened, surrendering nearly 30% of earlier gains. In spite of revealing a surprising first-quarter earnings report with a net sale of $882 million, down 29% from last year, GameStop’s stock declined. The gaming retail giant also… [Read More]
June 06, 2024

Aethlon Medical to Initiate Clinical Trial for Blood Purification Device

Medical Therapeutics company, Aethlon Medical (Nasdaq: AEMD) is topping the PRISM MarketView Medical Devices Index during the day on Thursday. The company provided an update this week on its planned Phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy… [Read More]